Sizing up the Oral Alternatives for MS

Sizing up the oral alternatives for MS

Two milestones were met late last month in the race to get the first oral treatment for multiple sclerosis to market: Merck KGaA submitted an NDA for its cladribine to treat relapsing-remitting MS; and Novartis AG reported Phase III data from a placebo-controlled trial of fingolimod.

While the data suggest both compounds are more efficacious than Copaxone glatiramer and the interferons that are used as first-line therapy for RRMS, safety issues could relegate them to second-line use along with Tysabri natalizumab, an injectable mAb against integrin alpha(4) that by one measure appears

Read the full 970 word article

User Sign In